SCYNEXIS, Inc. is a biopharmaceutical company dedicated to advancing treatments for severe rare diseases, focusing on difficult-to-treat and drug-resistant fungal infections. The company developed ibrexafungerp (BREXAFEMME), the first FDA-approved triterpenoid antifungal, licensed to GSK in 2023 for VVC and rVVC. SCYNEXIS is also developing SCY-247, a second-generation fungerp antifungal currently in Phase 1 clinical trials, targeting invasive candidiasis and other fungal infections.
Q2 FY2026 — expected 2026-09-21
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-04 | 2025-12-31 | 0001178253-26-000007 | EDGAR | 60K words |
| 2025-03-12 | 2024-12-31 | 0000950170-25-038044 | EDGAR | — |
| 2024-03-28 | 2023-12-31 | 0000950170-24-038046 | EDGAR | — |
| 2023-03-31 | 2022-12-31 | 0000950170-23-011138 | EDGAR | — |
| 2022-03-29 | 2021-12-31 | 0001564590-22-012199 | EDGAR | — |
| 2021-03-29 | 2020-12-31 | 0001564590-21-015962 | EDGAR | — |
| 2020-03-11 | 2019-12-31 | 0001564590-20-009875 | EDGAR | — |
| 2019-03-14 | 2018-12-31 | 0001564590-19-007834 | EDGAR | — |
| 2018-03-13 | 2017-12-31 | 0001564590-18-005461 | EDGAR | — |
| 2017-03-13 | 2016-12-31 | 0001178253-17-000001 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-11-05 | 2025-09-30 | 0001178253-25-000010 | EDGAR | 18K words |
| 2025-08-13 | 2025-06-30 | 0000950170-25-107985 | EDGAR | — |
| 2025-05-15 | 2025-03-31 | 0000950170-25-072548 | EDGAR | — |
| 2024-11-06 | 2024-09-30 | 0000950170-24-122241 | EDGAR | — |
| 2024-08-08 | 2024-06-30 | 0000950170-24-093856 | EDGAR | — |
| 2024-05-08 | 2024-03-31 | 0000950170-24-055590 | EDGAR | — |
| 2023-11-13 | 2023-09-30 | 0000950170-23-062894 | EDGAR | — |
| 2023-08-14 | 2023-06-30 | 0000950170-23-042362 | EDGAR | — |
| 2023-05-10 | 2023-03-31 | 0000950170-23-020486 | EDGAR | — |
| 2022-11-09 | 2022-09-30 | 0000950170-22-023822 | EDGAR | — |
| 2022-08-15 | 2022-06-30 | 0001564590-22-029486 | EDGAR | — |
| 2022-05-12 | 2022-03-31 | 0001564590-22-019843 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-03-31 | 0001193125-26-134476 | EDGAR | 1K words |
| 2026-03-31 | 0001193125-26-133259 | EDGAR | — |
| 2026-03-31 | 0001193125-26-133250 | EDGAR | — |
| 2025-10-15 | 0001178253-25-000006 | EDGAR | — |
| 2025-07-01 | 0000950170-25-092176 | EDGAR | — |
| 2025-06-26 | 0000950170-25-090374 | EDGAR | — |
| 2024-11-06 | 0000950170-24-122291 | EDGAR | — |
| 2024-09-10 | 0000950170-24-104918 | EDGAR | — |
| 2024-06-20 | 0000950170-24-075321 | EDGAR | — |
| 2024-03-28 | 0000950170-24-038015 | EDGAR | — |
192 total filings indexed. 160 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001178253 |
| Ticker | SCYX |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Website | https://www.scynexis.com |
| Listed | 2014-05-02 |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report